The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Dopamine D2 Receptors as Treatment Targets in Schizophrenia
Abstract
The antipsychotic effectiveness of chlorpromazine and haloperidol started a search for their therapeutic targets. The antipsychotic receptor target turned out to be a dopamine receptor, now cloned as the dopamine D2 receptor. The D2 receptor is the common target for antipsychotics. Antipsychotic clinical doses correlate with their affinities for this receptor. Therapeutic doses of antipsychotics occupy 60 to 80% of brain D2 receptors in patients, but aripiprazole occupies up to 90%. While antipsychotics may take up to six hours to occupy D2 receptors, much clinical improvement occurs within a few days. The receptor has high- and low-affinity states. The D2High state is functional for dopamine-like agonists such as aripiprazole. Most individuals with schizophrenia are supersensitive to dopamine. Animal models of psychosis show that a variety of risk factors, genetic and nongenetic, are associated with behavioral supersensitivity to dopamine, reflected in elevated levels of dopamine D2High receptors. Although antipsychotics such as haloperidol alleviate psychosis and reverse the elevation of D2High receptors, long-term use of traditional antipsychotics can further enhance dopamine supersensitivity in patients. Therefore, switching from a traditional antipsychotic to an agonist antipsychotic such as aripiprazole can result in the emergence of psychotic signs and symptoms. Clozapine and quetiapine do not elicit parkinsonism and rarely result in tardive dyskinesia because they are released from D2 within 12 to 24 hours. Traditional antipsychotics remain attached to D2 receptors for days, preventing relapse, but allowing accumulation that can lead to tardive dyskinesia. Future goals include imaging D2High receptors and desensitizing them in early-stage psychosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Self-citationKapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Self-citationPatil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Multiple dopamine D4 receptor variants in the human population
Tol, H. H. M. V., Wu, C. M., Guan, H.-C., Ohara, K., Bunzow, J. R., Civelli, O., Kennedy, J., Seeman, P., Niznik, H. B., & Jovanovic, V. (1992) · Nature · doi:10.1038/358149a0 · Cited by 955
Self-citationKellendonk, C., Simpson, E. H., Polan, H. J., Malleret, G., Vronskaya, S., Winiger, V., Moore, H., & Kandel, E. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.023 · Cited by 520
Delayed-Onset Hypothesis of Antipsychotic Action: A Hypothesis Tested and Rejected
Agid, O., Kapur, S., Arenovich, T., & Zipursky, R. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.12.1228 · Cited by 408
Seeman, P., & Tallerico, T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.876 · Cited by 237
Self-citationNeuroleptic-induced supersensitivity psychosis
(1978) · American Journal of Psychiatry · doi:10.1176/ajp.135.11.1409 · Cited by 224
Cited by
Moghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035
Study, L. C., Okbay, A., Baselmans, B. M. L., De Neve, J.-E., Turley, P., Nivard, M. G., Fontana, M. A., Meddens, S. F. W., Linnér, R. K., Rietveld, C. A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3552 · Cited by 1,013
Brisch, R., Saniotis, A., Wolf, R., Bielau, H., Bernstein, H.-G., Steiner, J., Bogerts, B., Braun, A. K., Jankowski, Z., Kumaritlake, J., et al. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00047 · Cited by 517
Update on Typical and Atypical Antipsychotic Drugs
Meltzer, H. Y. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050911-161504 · Cited by 433
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270
Current Enlightenment About Etiology and Pharmacological Treatment of Autism Spectrum Disorder
Eissa, N., Al-Houqani, M., Sadeq, A., Ojha, S. K., Sasse, A., & Sadek, B. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00304 · Cited by 260
All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2High Receptors
Seeman, P. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00162.x · Cited by 228
“; Reproduced from [31] with permission fromWalsh Medical Media LLC).”
BackgroundMethodInfluentialSelf-citationWilkinson, C. W., Pagulayan, K. F., Petrie, E. C., Mayer, C. L., Colasurdo, E. A., Shofer, J. B., Hart, K. L., Hoff, D., Tarabochia, M. A., & Peskind, E. R. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00011 · Cited by 162
Neuroglialpharmacology: Myelination as a shared mechanism of action of psychotropic treatments
Bartzokis, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.015 · Cited by 142
De Simone, G., Mazza, B., Vellucci, L., Barone, A., Ciccarelli, M., & de Bartolomeis, A. (2023) · Antioxidants · doi:10.3390/antiox12040975 · Cited by 49
Rolls, E. T. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.06.017 · Cited by 39
“) Thus D2 antagonists would, in a hypersensitive D2 receptor state (Seeman, 2010), increase GABA inhibition in the network, and this we suggest could increase the stability of attractor networks involved in the positive symptoms of schizophrenia.”
Norman, A. B., Tabet, M. R., Norman, M. K., Fey, B. K., Tsibulsky, V. L., & Millard, R. W. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.183244 · Cited by 10
Galan‐Rodriguez, B., Martin, E., Brouillet, E., Déglon, N., Betuing, S., & Caboche, J. (2017) · European Journal of Neuroscience · doi:10.1111/ejn.13415 · Cited by 5
“In addition to its important role in striatal vulnerability in HD, alterations of D2R-dependent signaling have been implicated in other brain pathologies such as schizophrenia, attention deficit hyperactivity disorder, Tourette syndrome, obsessive–compulsive disorder, Parkinson’s disease, and drug addiction (Iversen &…”
Metadata
- Authors
- Seeman, P.
- Venue
- Clinical Schizophrenia & Related Psychoses
- Publisher
- Longdom Group
- Published
- 2010-04
- Volume
- 4
- Issue
- 1
- Pages
- 56-73
- ISSN
- 1935-1232 (ISSN-L)
- OpenAlex
- W2091991835
- Cited by
- 193
- References
- 12
- FWCI
- 11.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.